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Abstract
Background: A 26-valent Group A Streptococcus (GAS) vaccine candidate has been developed that may provide
protection against pharyngitis, invasive disease and rheumatic fever. However, recommendations for the use of a
new vaccine must be informed by a range of considerations, including parents’ preferences for different relevant
health outcomes. Our objectives were to: (1) describe parent preferences for GAS disease and vaccination using
willingness-to-pay (WTP) and time trade-off (TTO) methods; and (2) understand how parents’ implied WTP for a
quality-adjusted life year (QALY) gained might vary depending on the particular health outcome considered (e.g.
averted GAS disease vs. vaccine adverse events).
Methods: Telephone interviews were conducted with parents of children diagnosed with GAS pharyngitis at 2
pediatric practice sites in the Boston metropolitan area. WTP and TTO (trading parental longevity for child’s health)
questions for 2 vaccine and 4 disease-associated health states were asked using a randomly selected opening bid,
followed by a 2nd bid and a final open-ended question about the amount willing to pay or trade. Descriptive
analyses included medians and interquartile ranges for WTP and TTO estimates. The Wilcoxon signed-rank test was
used to assess differences in WTP/QALY values for vaccine adverse events vs. disease states.
Results: Of 119 respondents, 100 (84%) and 96 (81%) provided a complete set of responses for WTP and TTO
questions, respectively. The median WTP and discounted (at 3% per year) TTO values to avoid each health state
were as follows: local reaction, $30, 0.12 days; systemic reaction, $50, 0.22 days; impetigo, $75, 1.25 days; strep
throat, $75, 2.5 days; septic arthritis, $1,000, 6.6 days; and toxic shock syndrome, $3,000, 31.0 days. The median
WTP/QALY was significantly higher for vaccine adverse events (~$60,000/QALY) compared to disease states
($18,000 to $36,000/QALY).
Conclusions: Parents strongly prefer to prevent GAS disease in children compared to vaccine adverse events.
However, implied WTP/QALY ratios were higher for the prevention of vaccine adverse events. Regret for errors of
commission vs. omission may differ and should be considered by vaccine policymakers.
Background
Group A Streptococcus (GAS) is responsible for up to
2.6 million cases of pharyngitis in children each year
and 1.1 million cases in adults in the U.S., with an esti-
mated economic burden of $224-539 million annually
due to GAS pharyngitis [1,2]. In addition, infection with
GAS causes up to 9,700 cases of invasive disease and
1,300 deaths annually [3,4]. The clinical spectrum of
invasive GAS disease is broad and may include bactere-
mia, pneumonia, septic arthritis, osteomyelitis,
meningitis, necrotizing fasciitis, or streptococcal toxic
shock syndrome [4-7].
Recently, a 26-valent GAS vaccine candidate was
developed that may provide protection against pharyngi-
tis, invasive disease and rheumatic fever [8,9]. Such a
vaccine may reduce the burden of GAS disease by up to
85% in the U.S [4,10,11]. However, parental preferences
regarding the prevention of disease vs. the risk for
minor vaccine adverse events should be explicitly con-
sidered before recommending widespread use of a GAS
vaccine. This is particularly relevant as concerns about
vaccine safety have become prominent, and the number
of parents refusing to vaccinate their children continues* Correspondence: grace_lee@hphc.org
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to grow as perceptions about the risks of vaccination
may outweigh perceived benefits [12-15].
Estimating preferences for childhood vaccination pro-
grams has been challenging for several reasons. First,
parents often serve as proxy respondents for young chil-
dren, raising concerns about how to distinguish the
child’s well-being from the parent’s altruism [16-18].
However, since parents are responsible for decision-
making about vaccinating their own children, and young
children are often unable to provide quantitative assess-
ments of their preferences, the choice of parents as a
proxy may be appropriate. Second, while many of the
older childhood vaccines have been focused on prevent-
ing chronic disability and death (e.g. neurologic disabil-
ity and death after Haemophilus influenzae type b
infection, paralysis and death after polio infection),
newer vaccines may target health conditions that are
temporary in duration (e.g. otitis media and bacteremia
in pneumococcal infection) [19,20]. Health states that
are described as short-term may be valued differently
than the same health states as chronic conditions
[21-23]. Third, off-the-shelf utilities do not exist for
many of the short-term health conditions, necessitating
a formal assessment of preferences when implementing
a new vaccination program. Finally, although many
childhood vaccination programs have historically been
found to be cost-saving, the higher prices associated
with several newer vaccines and rising emphasis on con-
cerns about vaccine safety require explicit examination
of the costs and health consequences of new programs
[12-15]. An empirical assessment of the willingness-to-
pay for a quality-adjusted life year gained may provide
important information for decision-makers in the con-
text of national vaccine policy.
Thus, our objectives were to: (1) describe parent pre-
ferences for GAS disease and vaccination using willing-
ness-to-pay (WTP) and time trade-off (TTO) methods,
and (2) understand how parent’s implied WTP for a
quality-adjusted life year (QALY) gained might vary
depending on the particular health outcome considered
(e.g. averted GAS disease vs. vaccine adverse events).
Methods
Study Population
Telephone interviews were conducted with parents of
children diagnosed with GAS pharyngitis at two pedia-
tric practice sites in the Boston metropolitan area. We
identified 236 potentially eligible episodes of GAS
pharyngitis among children who were seen at one
urban and one suburban practice for urgent care visits
from October 1, 2005 to January 25, 2006. Families
were considered eligible for the study if the child or
adolescent was less than 18 years of age, had symp-
toms consistent with strep throat and a confirmed
diagnosis of GAS pharyngitis with a positive rapid
strep test or throat culture.
Fifty-two cases were excluded from the study for the
following reasons: incorrect address or telephone num-
ber (22), child already had a sibling enrolled in the
study (12), child previously enrolled in the study (7),
taken to the doctor by someone other than a parent or
guardian (7), parent or guardian did not understand that
child had GAS pharyngitis (3), and parent or guardian
was non-English speaking (2). Of the 236 potentially eli-
gible children seen during the study period, 135 (57%)
parents agreed to participate in the study. Among these
parents, 16 were initially selected to pilot the prefer-
ences survey, and 119 parents received the final survey.
Survey
The telephone survey included questions about parent
preferences for avoiding short-term health states asso-
ciated with GAS disease and vaccination in their child
including impetigo, strep throat, septic arthritis, and
streptococcal toxic shock syndrome (Please see Addi-
tional File 1). Parents were asked both willingness-to-
pay (WTP) and time trade-off (TTO) questions about
each health state. In addition, information was collected
on demographics, duration of illness, medical costs, and
non-medical costs associated with episodes of GAS
pharyngitis in children.
For WTP questions, respondents were asked “Using
money that is available to you today, think about how
much money you would be willing to pay to prevent your
children from having this condition.” The framing of the
question in terms of currently available resources was
intended to elicit the amounts that individuals would actu-
ally pay in order to enhance the validity of the study; a dis-
advantage of this approach is that higher respondent
incomes would likely be associated with higher WTP [24].
Interviewers presented respondents with a randomly
selected opening bid (high, intermediate, low) for each
health state (Please see additional File 2). If respondents
were willing to pay the opening bid, they were asked if
they would be willing to pay a higher amount to avoid the
health state in question. If respondents were not willing to
pay the opening bid, they were asked if they would be will-
ing to pay a lower amount. After their response to the sub-
sequent bid, interviewers asked, “What is the most you
would be willing to pay?”.
For TTO questions, respondents were instructed as fol-
lows: “Think about how many hours or days you would be
willing to give up from the end of your life in order to pre-
vent your child from having this condition.” Of note, all
health conditions were described as being short-term and
the duration of each health state was described, ranging
from 2 days to 3 weeks. Similar to WTP, respondents
were given a high, intermediate, or low opening bid in
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terms of hours or days traded to prevent illness in their
child. After answering, a subsequent bid was offered and
then parents were asked, “What is the most you would be
willing to trade?” Because parents were asked to trade
time from the end of their lives, we estimated the impact
of alternative assumptions about discounting (0-5%) of
future health outcomes.
Statistical analyses
Final responses to the binary plus follow-up questions
for WTP (N = 100) and TTO (N = 96) are presented as
medians and interquartile ranges (IQRs), in order to
minimize the impact of outliers, particularly since the
distributions of responses were skewed. Individuals who
either refused to answer (N = 7 for WTP; N = 12 for
TTO) or did not provide an open-ended response for
each of the health states (N = 12 for WTP; N = 11
for TTO) were excluded from our primary analysis, in
order to accommodate analysis of individual rankings of
the set of health states. In a secondary analysis, we also
estimated predicted values for missing, interval or cen-
sored responses for each health state using a multivari-
able interval regression model that included age, gender,
and income as covariates. Comparison of results includ-
ing these predicted values allowed us to understand the
impact of missing data on the primary analyses. To
understand the impact of income on WTP estimates, we
calculated Spearman’s rank correlation coefficients.
Disutilities for short-term health states were calculated
using a previously published method [21]. The numerator
is the difference between the discounted stream of normal
life expectancy (LE) for the respondent, in years, and the
discounted stream of shortened LE, calculated as (1/r)*(1-
e(-r)*(LE of respondent)) - (1/r)*(1-e(-r)*(LE of respondent - time
traded)), where r is the discount rate. We interpret this
expression as the number of QALYs given up by the par-
ent to avoid having the child live with the health outcome
under consideration. The denominator is the duration of
the health state for the child that begins at the present
time, discounted accordingly for consistency, calculated as
(1/r) * [1-e(-r) (duration of health state)]. We assumed that the
maximum amount of discounted time traded from the
end of the respondent’s life could not exceed the (dis-
counted) duration of the health state, which anchors the
lowest time tradeoff value at zero. To calculate WTP for a
QALY, we divided the WTP response by the same expres-
sion used in the numerator of the disutility calculation
above, as this represents the QALY equivalent for the
health outcome:
WTP QALY WTP 1 r 1 e
1 r 1
r LE of respondent/ / [ / *( )
/ *(
*( )   
   
 
e r LE of respondent time traded  *( ))]
Individual values for the WTP/QALY ratio were calcu-
lated and medians and interquartile ranges are reported
for each of the six health states described. Values for indi-
viduals who did not trade any time to avoid illness (i.e.
denominator equals zero) were excluded for that particu-
lar health state for WTP/QALY calculations, although
they were included in descriptive analyses for TTO
responses. The Wilcoxon signed-rank test was used to test
for differences in WTP/QALY values for each matched
pair of health states. Additionally, 95% bias-corrected con-
fidence intervals were calculated for the median WTP/
QALY for each health state using bootstrapping with
10,000 re-samples. We chose to use the non-parametric
bootstrapping method to derive our bias-corrected confi-
dence intervals, since it makes no assumptions about the
distribution of WTP/QALY value.
Results
Study population
Our study population included 119 parents of children
diagnosed with GAS pharyngitis. Respondents were
mostly female (91%), had at least some college education
(80%), and had annual household incomes greater than
or equal to $80,000 (50%). (Table 1) Among these
Table 1 Characteristics of respondents (N = 119)
N (%)
Age of respondent (in quartiles) (N = 118)
19-36 years 29 (24.6%)
37-40 years 32 (27.1%)
41-43 years 26 (22.0%)
44-62 years 31 (26.3%)
Female respondent (N = 119) 108 (90.8%)
Annual household income, 2005 US$ (N = 119)
<50,000 26 (21.9%)
50,000-<80,000 22 (18.5%)
> = 80,000 60 (50.4%)
Refused to answer 11 (9.2%)
Educational level (N = 117)
Up to high school graduate 22 (18.8%)
Some college/technical school 29 (24.8%)
College graduate 40 (34.2%)
Postgraduate 26 (22.2%)
Race/ethnicity (N = 117)
White 91 (77.8%)
African American 16 (13.7%)
Hispanic 4 (3.4%)
Other 6 (5.1%)
Survey version (N = 119)
Low opening bids 40 (33.6%)
Intermediate opening bids 41 (34.5%)
High opening bids 38 (31.9%)
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participants, 100 (84%) and 96 (81%) individuals pro-
vided open-ended responses to the WTP and TTO
questions, respectively, although 112 (94%) and 107
(90%) individuals provided at least some interval data
for WTP and TTO questions. Comparing those who
provided open-ended responses to those who did not,
there were no differences in age, gender, educational
level, or race/ethnicity. Respondents who refused to
report their annual household income were significantly
less likely to provide complete, open-ended responses to
WTP (p = 0.002) and TTO (p = 0.001) survey items.
Willingness-to-pay
The median WTP values for local and systemic reactions
associated with vaccination were $30 and $50, respectively
(Table 2). Mild disease states associated with GAS infec-
tion such as impetigo and strep throat were associated
with higher median WTP values. Parents were willing to
pay the highest amounts to avoid severe disease such as
septic arthritis ($1,000) or streptococcal toxic shock syn-
drome ($3,000). Nonetheless, some respondents reported
they would not be willing to pay any amount of money
($0) to avoid the following health states: local reaction
(12%), systemic reaction (6%), impetigo (4%), and strep
throat (3%). Income was significantly correlated with WTP
estimates for the most severe health states such as septic
arthritis (r = 0.286, p = 0.003) and streptococcal toxic
shock syndrome (r = 0.289, p = 0.003); however, there
was no correlation between income and WTP values for
local reaction, systemic reaction, impetigo, or strep throat.
In secondary analyses that included predicted values for
missing, interval, or censored data, the median WTP was
the same or nearly the same for all states: local reactions
($30), systemic reactions ($50), impetigo ($75), strep
throat ($85), septic arthritis ($1,000), and toxic shock syn-
drome ($3,233).
Time trade-off
We calculated the present value of the median number
of days traded assuming discount rates of 0%, 3%, and
5% (Table 2). If we assumed that respondents dis-
counted future time at 3% per year, the median number
of days traded for a local reaction was 0.12 days com-
pared to 31.0 days traded to avoid a case of toxic shock
syndrome (Table 2). Of note, some respondents were
unwilling to trade any time (zero days) for the following
health states: local reaction (22%), systemic reaction
(18%), impetigo (17%), strep throat (14%), septic arthritis
(4%), and toxic shock syndrome (3%). For these short
term health states, median utilities were calculated for
local reactions (0.942), systemic reactions (0.892), impet-
igo (0.959), strep throat (0.925), septic arthritis (0.687),
and toxic shock syndrome (0.0). Accounting for the
duration of each health state (which ranged from 2 days
to 3 weeks), median estimates for QALYs in the year of
the infection were 0.9997 for local reactions, 0.9994 for
systemic reactions, 0.9986 for impetigo, 0.9977 for strep
throat, 0.9793 for septic arthritis, and 0.9063 for toxic
shock syndrome. In a secondary analysis, the inclusion
of predicted estimates for missing, interval or censored
variables provided similar estimates for days traded dis-
counted at 3%: local reactions (median 0.17; IQR [0.04-
0.44]), systemic reactions (median 0.24; IQR [0.06-0.54]),
impetigo (median 0.56; IQR [0.13-1.99]), strep throat
(median 0.75; IQR [0.27-3.5]), septic arthritis (median
10.5; IQR [3.5-30.5]), and toxic shock syndrome (median
41.5; IQR [8.3-134]).
WTP per QALY
The median implied WTP per QALY and 95% confi-
dence intervals were calculated across individuals for
each health state (Figure 1). Local reactions had a signif-
icantly higher WTP per QALY when compared to strep
throat (p = 0.006), septic arthritis (p = 0.029), or toxic
shock syndrome (p = 0.034). The median WTP per
QALY was also significantly higher for systemic reac-
tions compared to any of the health states associated
with GAS disease (impetigo, p = 0.012; strep throat, p =
0.033; septic arthritis, p = 0.008; toxic shock syndrome,
p = 0.022). When we included WTP per QALY
Table 2 Median open-ended WTP (N = 100) and TTO (N = 96) values for health states associated with Group A
Streptococcal disease and vaccination.




Median days traded discounted at
3% (25%-75%)
Median days traded discounted at
5% (25%-75%)
Local reaction $30 (10-50) 0.42 (0.15-1.0) 0.12 (0.04-0.33) 0.05 (0.01-0.16)
Systemic
reaction
$50 (20-50) 0.83 (0.19-1.83) 0.22 (0.05-0.43) 0.10 (0.02-0.19)
Impetigo $75 (35-112.5) 1.25 (0.42-7.0) 0.41 (0.11-1.99) 0.21 (0.04-0.78)
Strep throat $75 (30-150) 2.5 (0.50-10.0) 0.75 (0.15-3.61) 0.33 (0.07-1.83)
Septic arthritis $1,000 (250-
2,250)





90.0 (30.0-365.0) 31.0 (7.56-135.65) 14.2 (3.15-63.9)
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estimates based on predicted values, the median amount
remained significantly higher for local reactions vs. sep-
tic arthritis (p = 0.019), local reactions vs. toxic shock
syndrome (p = 0.044), systemic reactions vs. strep throat
(p = 0.010), systemic reactions vs. septic arthritis (p =
0.008), and systemic reactions vs. toxic shock syndrome
(p = 0.009).
Discussion
Parents were willing to trade more time and money to
avoid severe health states (i.e. septic arthritis, toxic
shock syndrome) associated with GAS disease vs. mild
GAS disease states (i.e. impetigo, strep throat) or minor
vaccine adverse events. The relative strength of prefer-
ence to avoid disease states, particularly severe condi-
tions, compared to minor vaccine adverse events has
been previously demonstrated [20,21]. Interestingly,
however, many vaccine cost-effectiveness analyses have
not typically considered the potential disutility asso-
ciated with vaccine adverse events in program evalua-
tions [19], perhaps because historically vaccines were
life-saving, so these minor adverse events were negligible
compared to the large overall benefits. As newer vac-
cines focus more on the prevention of morbidity, rather
than mortality, parental and patient preferences to avoid
both disease states and vaccine adverse events should be
explicitly considered.
Prior studies have estimated parental WTP to avoid
minor vaccine adverse events such as local or systemic
reactions. A 1999 study [20] reported a median paren-
tal WTP of $10 to $25 to reduce an infant’s pain and
emotional distress from childhood vaccination, while a
study in 2001 reported a WTP of $25 to prevent fever
and fussiness in young children after pneumococcal
conjugate vaccine administration [25]. Another study
conducted in 2002 examined parental WTP to avoid
local and systemic reactions in adolescents, and found
median estimates of $3 and $13, respectively [21]. Par-
ents in our study reported slightly higher WTP values
to prevent local ($30) and systemic ($50) reactions
after a GAS vaccine, which may reflect differences in
health state descriptions across studies, different con-
siderations by parents depending on the age of the
child (infant vs. toddler vs. adolescent), differences in
the socioeconomic status of our population, inflation,
or changes in the overall societal context regarding
vaccine safety.
Empirically calculating the implied WTP per QALY
may provide insight into the true societal WTP for
gains in health, which may be preferred to using the
persistent benchmark of $50,000 to $100,000 per QALY
saved [26]. Although the standard approach in cost-
effectiveness analysis relies on benchmarks for high-
value interventions using the same threshold value for
the WTP per QALY for all interventions, we observe
substantial differences in the WTP per QALY to avoid
different health states. In our study, parents were willing
to pay more per incremental health gain to avoid vac-
cine adverse events (~$60,000 per QALY) compared to
avoiding health states associated with GAS disease
(~$18,000 to $36,000 per QALY). If these differences
relate to true variability in the relative importance
Figure 1 Median (IQR) WTP per QALY.
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parents place on different types of outcomes, after con-
trolling for the duration and severity of these outcomes,
an important implication is that increased attention
should focus on minimizing potential complications in
healthy individuals. While it has previously been shown
that treatment interventions are strongly preferred by
society to preventive interventions [27,28], we are not
aware of any studies that have explicitly compared pre-
ferences regarding vaccine adverse events vs. disease
prevention.
Our findings that parents have a greater WTP per
QALY for preventing vaccine adverse events compared
to disease may be indicative of how individuals experi-
ence regret. An action, such as vaccinating a child,
resulting in a potential adverse event may generate
more regret than an inaction (i.e. refusing to vaccinate a
child), even if a child becomes ill with a preventable dis-
ease [29-31]. This phenomenon is often characterized in
terms of the distinction between “acts of commission”
and “acts of omission”, which is particularly relevant in
the case of vaccination [32]. Parents may feel more guilt
over agreeing to give a vaccine to their child that might
cause harm, particularly in the short term, when com-
pared to not vaccinating their child who by random
chance develops disease. This may be reinforced by the
changing perception of the risk-benefit balance by
society, where fewer individuals have direct experience
with vaccine-preventable diseases, furthering the intui-
tive response by some parents to focus more on vaccine
safety and concerns about harming their child [33].
Further exploration of how regret for errors of commis-
sion and omission may influence parental preferences in
vaccination programs is needed, particularly as new vac-
cines are recommended for use.
Our study has several limitations. First, our study
population was relatively small and limited to parents of
children who have experienced GAS pharyngitis. Con-
sideration should be given to obtaining community
values regarding GAS vaccination and disease [34]. Sec-
ond, parents may not have had a complete understand-
ing of the implications of these health states since our
descriptions were brief and interviews were conducted
by phone. As with any TTO, since parents were trading
time from the end of their life, they may have assumed
that they were trading time from a worse health state
than their present condition and potentially have biased
our TTO disutility estimates upward [35]. Third,
anchoring bias may have occurred for our WTP and
TTO estimates since we presented individuals with an
initial opening bid that may have affected subsequent
responses, although we did attempt to minimize this by
randomizing among 3 different starting bids [36].
Fourth, missing or incomplete responses may have
biased our WTP and TTO estimate in either direction.
In a secondary analysis, however, our findings did not
change significantly with the inclusion of predicted esti-
mates for these individuals based on their characteris-
tics. Fifth, WTP per QALY was inferred rather than
directly elicited. Additionally, the pattern of declining
WTP per QALY estimates for more severe health states
may be due in part to the insensitivity to scale in WTP
[37,38]. Finally, another key limitation of this study is
that information was not available regarding parental
refusal or deferral on any of their child’s vaccines, thus
we could not validate the WTP per QALY estimates
with actual changes in behavior patterns.
Our findings suggest that parents prefer to prevent
GAS disease in children compared to preventing minor
vaccine adverse events, but that parents are also willing
to pay more per QALY gained to prevent vaccine
adverse events. Parental preferences should be incorpo-
rated in decision-making by policymakers when imple-
menting new vaccination programs in the U.S.
Additional file 1: Description of health states.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1477-7525-8-28-
S1.DOC ]
Additional file 2: Description of high, intermediate and low bid
vectors used for WTP and TTO questions.
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